



Pfizer New Zealand Limited
NZBN: 9429040634296
Precinct Flex Britomart Level 10
11 Britomart Place Auckland 1010 New Zealand

19 October 2026

Dear Healthcare Professional,

IMPORTANCE NOTICE

Subject: Supply of Comirnaty XFG 10 micrograms/0.3 mL single-dose vial presentation in Canadian packaging for children aged 5 to 11 years

Pfizer New Zealand wishes to inform healthcare professionals of a supply arrangement for **Comirnaty XFG 10 micrograms/0.3 mL suspension for injection (single-dose vial)** for use in children aged **5 to 11 years only**.

To ensure continuity of supply and avoid disruption to COVID-19 vaccination programmes in New Zealand, Pfizer New Zealand will supply Comirnaty XFG 10 micrograms/0.3 mL **in Canadian packaging** under a Medsafe-approved labelling exemption.

Differences on Canadian label:

- Product name: Comirnaty (with "Omicron XFG" identifier)
- Bilingual pack with Information in English and French
- Pfizer Canada website and contact phone number
- QR code on the pack is a direct link to Canadian website and information
- Expiry date printing format ("2027-SE" printed for 2027/09) for storage at -90 °C to -60 °C

Information for healthcare professionals

The Canadian labelled vaccine supplied under this arrangement is the same Comirnaty XFG 10 micrograms/0.3 mL vaccine approved in New Zealand. There are **no changes** to the:

- vaccine formulation;
- active ingredient;
- strength;
- indication;
- dosage; or
- administration requirements.

Healthcare professionals will, however, notice the QR code on the carton label takes users to the Pfizer Canadian website and the information on this website, and the contact details on the carton label, are specific to residents of Canada. Please refer to Medsafe approved Data sheet for the vaccine for use in New Zealand.

Key points

- Canadian labelled packs of Comirnaty XFG 10 micrograms/0.3 mL single-dose vial will be supplied in New Zealand for use in children 5 to 11 years of age only.
- This arrangement has been implemented to maintain uninterrupted availability of vaccine supply.
- Expiry date for the batch is September 2027 (printed as “2027-SE” for 2027/09) for storage at -90 °C to -60 °C.
- Healthcare professionals should refer to the expiry date applied for 2 °C to 8 °C storage of thawed vaccine (maximum of 10 weeks).
- The vaccine should continue to be stored, prepared and administered in accordance with the approved New Zealand Data Sheet.
- Current New Zealand recommendations for use of Comirnaty COVID-19 vaccine remain unchanged.

Patient and caregiver enquiries

Parents and caregivers may notice that the packaging differs from previous New Zealand supplies.

Healthcare professionals can advise that:

- the product is being supplied under a Medsafe-approved labelling exemption;
- the vaccine itself is unchanged; and
- the supply of Canadian labelled packs has been implemented to support continuity of vaccine supply in New Zealand.

Please review the current New Zealand Data Sheet before prescribing or dispensing.

The New Zealand Data Sheet and Consumer Medicine Information can be found at

<https://medsafe.govt.nz/>

Further information

If you have any questions regarding this temporary supply arrangement, please contact Pfizer Medical Information:

Pfizer Medical Information

Phone: 0800 736 363 (11 AM - 7 PM NZST, Monday to Friday)

Website: www.pfizermedinfo.co.nz

Adverse event reporting

Healthcare professionals are encouraged to continue reporting suspected adverse reactions to the Centre for Adverse Reactions Monitoring (CARM) via

<https://pophealth.my.site.com/carmreportnz/s/> or to Pfizer on 0800 736 363 or by email to AUS.AEReporting@pfizer.com.

Thank you for your continued support in ensuring access to COVID-19 vaccination for eligible children in New Zealand.

Yours sincerely,

A handwritten signature in grey ink, appearing to read 'David Witcombe', with a stylized, cursive script.

David Witcombe
Director, Medical Affairs, Vaccines
Pfizer New Zealand Limited